CN1319637C - Chitose microsphere and microcapsule with uniform size and its preparation method - Google Patents
Chitose microsphere and microcapsule with uniform size and its preparation method Download PDFInfo
- Publication number
- CN1319637C CN1319637C CNB2003101002631A CN200310100263A CN1319637C CN 1319637 C CN1319637 C CN 1319637C CN B2003101002631 A CNB2003101002631 A CN B2003101002631A CN 200310100263 A CN200310100263 A CN 200310100263A CN 1319637 C CN1319637 C CN 1319637C
- Authority
- CN
- China
- Prior art keywords
- capsule
- micro
- chitosan
- size homogeneous
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003094 microcapsule Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims description 35
- 239000004005 microsphere Substances 0.000 title abstract description 10
- LKAPTZKZHMOIRE-KVTDHHQDSA-N (2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbaldehyde Chemical compound OC[C@H]1O[C@H](C=O)[C@@H](O)[C@@H]1O LKAPTZKZHMOIRE-KVTDHHQDSA-N 0.000 title 1
- LKAPTZKZHMOIRE-UHFFFAOYSA-N chitose Natural products OCC1OC(C=O)C(O)C1O LKAPTZKZHMOIRE-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 76
- 229920001661 Chitosan Polymers 0.000 claims abstract description 66
- 239000000839 emulsion Substances 0.000 claims abstract description 39
- 229940079593 drug Drugs 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 15
- 239000011806 microball Substances 0.000 claims description 47
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 31
- 210000003022 colostrum Anatomy 0.000 claims description 6
- 235000021277 colostrum Nutrition 0.000 claims description 6
- 230000004888 barrier function Effects 0.000 claims description 5
- 239000003431 cross linking reagent Substances 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 abstract description 12
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 102000004169 proteins and genes Human genes 0.000 abstract description 10
- 239000003937 drug carrier Substances 0.000 abstract description 9
- 238000013019 agitation Methods 0.000 abstract description 7
- 238000001727 in vivo Methods 0.000 abstract description 7
- 229920001184 polypeptide Polymers 0.000 abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 4
- 238000004945 emulsification Methods 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 239000005556 hormone Substances 0.000 abstract description 3
- 229940088597 hormone Drugs 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 2
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 abstract 2
- 238000003825 pressing Methods 0.000 abstract 2
- 238000007711 solidification Methods 0.000 abstract 2
- 230000008023 solidification Effects 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 45
- 235000019198 oils Nutrition 0.000 description 45
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 36
- 239000012071 phase Substances 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000002245 particle Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 230000002209 hydrophobic effect Effects 0.000 description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 210000004379 membrane Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000004132 cross linking Methods 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000010382 chemical cross-linking Methods 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 239000012982 microporous membrane Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- -1 anticancer Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 229920006318 anionic polymer Polymers 0.000 description 2
- 239000011805 ball Substances 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 238000005354 coacervation Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- JCZPMGDSEAFWDY-SQOUGZDYSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical compound NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO JCZPMGDSEAFWDY-SQOUGZDYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010054033 Chitin deacetylase Proteins 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000004955 epithelial membrane Anatomy 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 150000003613 toluenes Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention provides chitosan microsphere or microcapsule drug carriers with a uniform dimension and stable dispersibility for protein drugs, polypeptide drugs, anticancer drugs, hormone drugs and other hydrophilic drugs and oil soluble drugs, and the chitosan microsphere or microcapsule drug carriers are used for the controlled release and target administration, etc. of the hydrophilic drugs. The drug carriers are characterized in that the chitosan microsphere or microcapsule drug carriers with a uniform dimension and stable dispersibility are prepared by two methods: (1). one method comprises the following steps: dissolving the hydrophilic drugs in the acetic acid water solution of chitosan, pressing the water phase in an oil phase through microporous membranes by pressure to obtain emulsion drops with a uniform dimension; then solidifying the emulsion drops with a certain solidification method; (2). the other method comprises the following steps: dissolving the oil soluble drugs in an oily solvent, and the hydrophilic drugs in the acetic acid water solution of chitosan to prepare a primary emulsion O1/W by using a homogeneous phase emulsifier; pressing the primary emulsion in an oil phase through microporous membranes by pressure to obtain multiple emulsion drops (O1/W)/O2 with a uniform dimension; then solidifying the multiple emulsion drops with a certain solidification method. Under optimum conditions, the diameter distribution coefficient of the microspheres and the microcapsules can be controlled within 11%, and the diameter can be freely controlled from 1 to 100 micrometers; the technology solves the problems of non-uniform grain diameters, low embedding rate and poor dispersibility of the chitosan drug carriers prepared with the traditional agitation emulsification method, and has the prospects of solving the critical problems of stable drug release and in vivo utilization rate improvement of the drugs by utilizing the characteristic of uniform.
Description
Technical field
The invention belongs to the field of pharmaceutical preparations of pharmaceutical engineering
Background technology
The polysaccharide that shitosan is made up of aminoglucose and N-acetyl glucosamine copolymer is the product of chitin deacetylase base, and shitosan can be dissolved in dilute acid soln owing to have free amine group on the strand, therefore has purposes more widely than chitin.Shitosan is as a kind of cationic biopolymer, have bioadhesive, biocompatibility and biological degradability, and its catabolite is nontoxic, non-immunogenicity, non-carcinogenesis, and these uniquenesses of shitosan make it become the biological medicine carrier that has a extensive future
[1] [2] [3]
Shitosan mainly is to use with the form of microballoon or micro-capsule as the biological medicine carrier, can be used as the immobilization of the separating medium and the enzyme of protein as chitosan microball, owing to not only have hydroxyl but also have amino on the chitosan microball, can under the condition of gentleness, connect aglucon, be used as immobilization, immunity absorption and the Separation of Proteins medium of enzyme
[4]In addition by in chitosan solution, adding the chitosan microball that pore-foaming agent can be prepared macropore, this microballoon can be used as the carrier that cell is cultivated, nutrient and metabolite thereof can be by interconnective macropore input and output, this macroporous microsphere has two big major advantages as cell culture vector, can make cell avoid the influence of the shearing force of bioreactor in cell cultivation process, can improve the density that cell is cultivated on the other hand exactly greatly
[5]Chitosan microball mainly is because shitosan is a kind of cationic substance as genophore, its positive charge can form the compound microballoon with the negative electrical charge generation electrostatic interaction of DNA, can insert aglucon such as iron transfer protein, galactolipin etc. simultaneously and make it have better target on microballoon
[6]People such as Hai-Quan Mao adopt shitosan-DNA complex coacervation to prepare millimicro ball studies show that as genophore; shitosan can protect DNA to avoid the degraded of nuclease; the surface PEG (polyethylene glycol) of shitosan-DNA millimicro ball is changed; can improve the physical stability and the storage stability of microballoon; its freeze-drying prods good dispersion, adhesion, nor the transfection ability of reduction microballoon
[7]Chitosan microball or micro-capsule mainly concentrate on as slow releasing carrier of medication in the application of field of medicaments in recent years, and this mainly is based on chitosan microball or micro-capsule and has the toxic and side effect that strengthens drug absorption, sustained release performance, adhesiveness, immunostimulatory activity, anticoagulant property, antibiotic property, reduction medicine, prolongs advantages such as curative effect
[8]As as the consolidant of wound, it not only have sterilization and bacteriostasis, can accelerating wound healing, can also in gel, directly reach result of treatment efficiently by embedding medicinal at the wound slow releasing pharmaceutical
[8]Because shitosan has bioadhesive, put medicine by prolonging contained medicine at the gentle slow release of RT of affected part, can improve medicine bioavilability in vivo greatly, therefore become the ideal carrier of mucoadhesive delivery system
[9]Chitosan microball or micro-capsule can protected protein matter in addition, medicines such as polypeptide, nucleic acid exempt from digestive system and destroy, and make medicine can arrive the colon place smoothly and discharge medicine at this, reach optimum curative effect; Chitosan microball has many advantages as the vaccine slow-released carrier, and the firstth, shitosan dissolves in the aqueous acetic acid, has avoided with an organic solvent, and this provides advantageous conditions for the high activity that keeps antigen and protein; The secondth, because shitosan is a kind of cationic polyelectrolyte, it and electronegative cell surface have strong electrostatic interaction, vaccine or medicine are adsorbed on the epithelial membrane, improve medicine greatly cell and structural keeping, delay the release of medicine, compare with conventional medicament and can reduce medicine frequency
[10]The 3rd be shitosan as the carrier material of vaccine microballoon except possess improve penetrate with imbedibility and protection vaccine and slow releasing function; also has immunostimulatory activity; as increase the accumulation and the activity of macrophage and polymorphonuclear cell; improve opposing infected by microbes ability; the plain secretion of inducing cell improves cytotoxic T---lymphocytic immune response
[11], reduce medicine frequency simultaneously, overcome repeatedly in vivo the shortcoming that blood concentration fluctuation is big, side effect is big after the medication of traditional vaccine.Therefore shitosan is a kind of pharmaceutical grade protein carrier that has a extensive future.
Yet the preparation method of chitosan microball or micro-capsule is very limited at present, mainly adopts emulsion-crosslinking method, spray drying process and complex coacervation
[12] [13]And these preparation methods adopt mechanical mixing method mostly, adopt this method in preparation emulsion process, because particle diameter heterogeneity, little emulsion droplet can be absorbed by big emulsion droplet, big emulsion droplet can destroy because of the effect of shearing force again simultaneously, and this can cause very heterogeneity of prepared chitosan microball or microcapsule diameter.And because the particle diameter heterogeneity of emulsion droplet, by big drop absorption, big drop is sheared into droplet again to droplet easily, thereby can form a lot of cross-linked cohesion things easily in cross-linking process.Simultaneously, in the merging and rupture process of drop, interior bag medicine escapes into the drop outside easily, causes the embedding rate of medicine to reduce.Even after microballoon forms,, in the washing of product and dry run, also form condensation product easily because minimicrosphere is easily by big microballoon absorption.The heterogeneity of microballoon and micro-capsule also can be brought many difficulties for the practical application of chitosan microball or micro-capsule.For example, as the immobilization and the Separation of Proteins medium of enzyme, because the particle diameter heterogeneity, little microballoon can gather in pillar in the space between the big microballoon, makes separating pressure increase, and can cause when serious separating and can't carry out; As cell culture vector, the particle diameter heterogeneity can cause the inhomogeneous of nutrient and cell density, thereby causes the inhomogeneous of cell growth; As slow releasing carrier of medication,, because microballoon or microcapsule diameter heterogeneity make the target of medicine poor in being administered systemically, cause medicine bioavilability in vivo to reduce greatly in addition because the emulsion instability can cause the embedding rate of medicine to reduce greatly.Therefore be necessary to study novel preparation method, prepare uniform particle diameter chitosan microball or micro-capsule, so as to overcome the not enough of traditional preparation process method and the application that brings thus on defective.
Summary of the invention
This research provides the chitosan microball or the microcapsule medicament carrier of size homogeneous, stably dispersing at hydrophilic medicament and oil-soluble medicines such as protein, polypeptide, anticancer, hormones, with the control release that is used for hydrophilic medicament and target administration etc.It is characterized in that (1) is dissolved in hydrophilic medicament in the aqueous acetic acid of shitosan, this water is pressed in the oil phase by microporous barrier with pressure, obtain the emulsion droplet of size homogeneous, adopt certain curing that emulsion droplet is solidified then, obtain the chitosan microball or the microcapsule medicament carrier of size homogeneous, stably dispersing; (2) oil-soluble medicine is dissolved in the oil-based solvent, hydrophilic medicament is dissolved in the aqueous acetic acid of shitosan, is prepared into O with the homogeneous phase emulsifier earlier
1Behind/W the colostrum, this colostrum is pressed in the oil phase by microporous barrier with pressure, obtains (the O of size homogeneous
1/ W)/O
2Emulsion drips, and adopts suitable curing that emulsion droplet is solidified then, obtains the chitosan microball or the microcapsule medicament carrier of size homogeneous, stably dispersing.Under optimal conditions, the diameter breadth coefficient of microballoon and micro-capsule is controlled in 11%, and diameter can freely be controlled in the 1-100 micron.
Chitin medicine carrier particle diameter heterogeneity, the embedding rate that this technology has solved traditional stirring and emulsifying method preparation is low, the problem of bad dispersibility.Be expected to utilize the homogeneity characteristic of particle diameter, reach stable release medicine, improve the medicine key issue of utilization rate in vivo.
The chitosan microball of size homogeneous provided by the invention or microcapsule medicament carrier and preparation method thereof can also bring down column effect:
(1) chitosan microball provided by the invention or microcapsule medicament carrier can be used for multiple hydrophily of embedding and oil-soluble medicine, as cancer therapy drug mitomycin, adriamycin, taxol etc.; The particle diameter of regulation and control microballoon or microcapsule carrier can be used it for hypodermic injection, intravenous injection, lumbar injection, arterial embolism, oral etc.
(2) chitosan microball provided by the invention or microcapsule medicament carrier because uniform particle diameter and controlled, use this pharmaceutical carrier can carry out relation research between particle diameter and different pharmaceutical and the result of treatment thereof.This is because particle diameter and its distributing position and time in vivo of carrier have bigger relation, as pharmaceutical carrier, the different medicines curative effect that diverse location produced in vivo may be different, the pharmaceutical carrier that different pharmaceutical is prepared a series of particle diameters, and medication respectively, can find out the medication effect of different pharmaceutical, thereby find out the required optimum grain-diameter scope of different pharmaceutical at different-grain diameter.If the size heterogeneity of pharmaceutical carrier then can't be carried out the research of this respect.
(3) preparation method provided by the invention, mild condition is expected to keep the high activity of biologically active drug.
(4) microballoon provided by the invention and microcapsule diameter homogeneous are expected to realize that control stable, favorable reproducibility discharges.
Description of drawings
The preparation flow of Fig. 1 chitosan microball or microcapsule medicament carrier.
The light micrograph of the chitosan microball of Fig. 2 embodiment 1 preparation.
The light micrograph of the chitosan microball of Fig. 3 comparative example 1 preparation.
Fig. 4 embodiment 2 adopts the light micrograph of the chitosan microball of different membrane aperture preparations.
(chitosan microballs (A:4.7 μ m, B:5.7 μ m, C:13 μ m, D:19.6 μ m) of different membrane aperture preparations)
Graph of a relation between the chitosan microball particle diameter of the different membrane aperture of Fig. 5 embodiment 2 preparations and the membrane aperture.
The microphoto of the microballoon of the different chitosan concentrations of Fig. 6 embodiment 3 preparations.
(the microballoon microphoto of different chitosan concentrations (A:1.0wt%, B:1.5wt%, C:2.0wt%))
Fig. 7 drug bearing microsphere light micrograph.
The calibration curve of the model protein BSA (bovine serum albumin) of 4 embeddings of Fig. 8 embodiment.
Specific embodiments
The present invention includes the hydrophilic medicament chitosan microball of size homogeneous or microcapsule carrier and preparation method thereof.The chitosan microball of pharmaceutical grade protein or the preparation of microcapsule carrier are by step preparation shown in Figure 1, and concrete grammar and step are described as follows:
1) w/o type emulsion or (O
1/ W)/O
2The preparation of type emulsion
Hydrophilic medicament, shitosan, NaCl and other additive are dissolved in the certain density acetum, as water; More than one oil soluble emulsifying agent is dissolved in oil-based liquid, as oil phase.Water is pressed into oil phase by hydrophobic porous film, obtains the w/o type emulsion of size homogeneous.
When wanting the embedding oil-soluble medicine, oil-soluble medicine directly can be dispersed in the above-mentioned chitosan aqueous solution, maybe it can be dissolved in earlier in the oily matter, make interior oil phase (O
1) after, mix with above-mentioned chitosan aqueous solution with this oil phase, with homogeneous phase emulsifier or ultrasonic emulsator emulsification, make O
1Behind/W type the colostrum, colostrum is pressed into outer oil phase (O by hydrophobic porous film
2), obtain (the O of size homogeneous
1/ W)/O
2The type emulsion.
Hydrophilic medicament comprises anticancer, vaccine, nucleic acid, RNA and albumin, hemoglobin, colony stimulating factor, interferon, insulin and other each proteinoid and polypeptide drugs etc., in can being soluble in the aqueous phase together or separately as required; Interior water additive can comprise harmless water-soluble substanceses such as albumin, lecithin, glucose, sweet mellow wine.Oil-soluble medicine comprises hormone, anticancer and other various oil-soluble medicines.Oil phase is to be liquid under the normal temperature, with the immiscible oily matter of water, can use atoleine and benzinum, olive oil, cotton seed oil, soya-bean oil, sunflower oil, other alkanes hydrocarbon etc.Oil emulsifier must be dissolved in employed oily matter, can use polymer (as PO-500, PO-310), Crodaret, sorbitan trioleate (class of department 85), sorbitan monooleate (class of department 80), anhydrous sorbitol tristearate (class of department 65), the oleophylic-hydrophilic block copolymers of sorbitan sesquioleate (Arlace183), glycerin ether etc.The concentration of emulsifying agent is 0.5-10wt% in the oil phase.
The volume ratio of water and oil phase is 1: 1-1: 1000.
2) preparation of chitosan microball or micro-capsule
With above-mentioned steps 1) after the emulsion of gained adopts suitable emulsifying agent to be cured, washing, dry finished product chitosan microball or micro-capsule.Curing agent comprises the chemical cross-linking agent that can make chitosan molecule generation chemical crosslinking, makes the inorganic salt solution of shitosan dehydration, organic slat solution, alkaline solution and and the anionic polymer of shitosan generation ion complex (multiple cohesion).
Chemical cross-linking agent can use the saturated toluene solution of glutaraldehyde (GST), the aqueous solution of glutaraldehyde, formalin, epoxide, and the amount ranges of chemical cross-linking agent is that the mol ratio of the amino of aldehyde radical or epoxy radicals and shitosan is 1: 1-1: 10; Crosslinking time is 0.5-5h, and crosslinked temperature is 18-50 ℃, and the oil phase revolution is 150-500rpm when crosslinked.
Inorganic and organic slat solution comprises Na
2SO
4, NaCl, tripolyphosphate, sodium acetate etc. can make the material of shitosan dehydration.
Alkaline solution comprises that NaOH, KOH, ammoniacal liquor, organic amino etc. make the material of shitosan dehydration with the chitosan-acetic acid solution neutralization.
Anionic polymer comprises alginic acid or alginate, carragheen, gelatin, casein, polyacrylic acid acid and copolymer, polymethylacrylic acid and copolymer thereof etc.
After curing reaction finished, successively with benzinum, acetone, ethanol, acetone washing, vacuum drying 48h got finished product chitosan microball or micro-capsule with thus obtained microsphere.
Embodiment 1
With the aperture is that the hydrophobic film of 4.7 μ m places oil loving material to soak into, and makes pore membrane fully moistening to guarantee the complete spread apart of hydrophobic chain on the film.The aqueous acetic acid of preparation 1wt% adds a certain amount of NaCl and under agitation to make its dissolving, its concentration be 1wt%, and adding certain amount of chitosan then, to make its concentration be 2wt%, treat that it dissolves fully after, solution is filtered standby.Oil soluble emulsifying agent is joined among the mixing oil phase 60ml of atoleine and benzinum, be stirred to fully and dissolve as oil phase.Under certain pressure, the hydrophobic microporous membrane by the aperture homogeneous is pressed in the oil phase, obtains the w/o type emulsion with the water of 6.0g; Slowly drip GST and carry out crosslinked (mol ratio amino and aldehyde radical is 1: 1) in the gained emulsion, crosslinkedly carry out at normal temperatures, the oil phase revolution is 300rpm when crosslinked, and crosslinking time is 2h; Crosslinked end is used benzinum, acetone, ethanol and acetone washing successively with the chitosan microball of gained, and vacuum drying 48h gets the finished product microballoon.The average grain diameter of emulsion adopts the microscope that has scale to measure, and surveys 200 and averages, and average diameter is 12.92 μ m, and the CV value is 19.70%.Optical microscope photograph as shown in Figure 2, particle diameter is homogeneous comparatively.
Comparative example 1 (mechanical mixing method)
Adopt the prescription identical with example 1, the aqueous acetic acid of preparation 1wt% adds a certain amount of NaCl and also under agitation makes its dissolving, its concentration is 1wt%, adding certain amount of chitosan then, to make its concentration be 2wt%, treat that it dissolves fully after, solution is filtered standby.Oil soluble emulsifying agent is joined among the mixing oil phase 60ml of atoleine and benzinum, be stirred to fully and dissolve as oil phase.The water of getting 6.0g mixes with oil phase, magnetic agitation 1000rpm, and 30min obtains the w/o type emulsion; Slowly drip GST and carry out crosslinked (mol ratio amino and aldehyde radical is 1: 1) in the gained emulsion, crosslinkedly carry out at normal temperatures, the oil phase revolution is 300rpm when crosslinked, and crosslinking time is 2h; Crosslinked end is used benzinum, acetone, ethanol and acetone washing successively with the chitosan microball of gained, and vacuum drying 48h gets the finished product microballoon.The average grain diameter of emulsion adopts the microscope that has scale to measure, and surveys 200 and averages, and average diameter is 117.60 μ m, and the CV value is up to 69.90%.Optical microscope photograph as shown in Figure 3, the particle diameter non-constant width that distributes.
Embodiment 2
The hydrophobic film that the aperture is respectively 4.7 μ m, 5.7 μ m, 13 μ m, 19.6 μ m places oil loving material to soak into, and makes pore membrane fully moistening to guarantee the complete spread apart of hydrophobic chain on the film.The aqueous acetic acid of preparation 1wt% adds a certain amount of NaCl and under agitation to make its dissolving, its concentration be 1wt%, and adding certain amount of chitosan then, to make its concentration be 1.5wt%, treat that it dissolves fully after, solution is filtered standby.Oil soluble emulsifying agent is joined among the mixing oil phase 60ml of atoleine and benzinum, be stirred to fully and dissolve as oil phase.Under certain pressure, the hydrophobic microporous membrane by various apertures homogeneous is pressed in the oil phase respectively, obtains the w/o type emulsion with the water of 6.0g; Slowly drip GST and carry out crosslinked (mol ratio amino and aldehyde radical is 1: 1) in the gained emulsion, crosslinkedly carry out at normal temperatures, the oil phase revolution is 300rpm when crosslinked, and crosslinking time is 2h; Crosslinked end is used benzinum, acetone, ethanol and acetone washing successively with the chitosan microball of gained, and vacuum drying 48h gets the finished product microballoon.The average grain diameter of emulsion adopts the microscope that has scale to measure, surveying 200 averages, average diameter is respectively 13.81 μ m, 21.14 μ m, 32.11 μ m, 59.94 μ m, optical microscope photograph as shown in Figure 4, graph of a relation between microspherulite diameter and the membrane aperture as shown in Figure 5, by linear between the aperture of microspherulite diameter and film as can be seen on the figure, microspherulite diameter approximately is about 3 times of membrane aperture.
Embodiment 3
With the aperture is that the hydrophobic film of 4.7 μ m places oil loving material to soak into, and makes pore membrane fully moistening to guarantee the complete spread apart of hydrophobic chain on the film.The aqueous acetic acid of preparation 1wt%, adding a certain amount of NaCl and under agitation making its dissolving, its concentration is 1wt%, adds certain amount of chitosan then and makes its concentration be respectively 1.0wt%, 1.5wt% and 2.0wt%, after treating that it dissolves fully, solution is filtered standby.Oil soluble emulsifying agent is joined among the mixing oil phase 60ml of atoleine and benzinum, be stirred to fully and dissolve as oil phase.Under certain pressure, the hydrophobic microporous membrane by the aperture homogeneous is pressed in the oil phase, obtains the w/o type emulsion with the water of 6.0g; Slowly drip GST and carry out crosslinked (mol ratio amino and aldehyde radical is 1: 1) in the gained emulsion, crosslinkedly carry out at normal temperatures, the oil phase revolution is 300rpm when crosslinked, and crosslinking time is 2h; Crosslinked end is used benzinum, acetone, ethanol and acetone washing successively with the chitosan microball of gained, and vacuum drying 48h gets the finished product microballoon.The average grain diameter of emulsion adopts the microscope that has scale to measure, and surveys 200 and averages, and average diameter is respectively 17.40 μ m, 13.81 μ m and 12.92 μ m, and the CV value is respectively 21.94%, 13.35% and 19.70%.Optical microscope photograph as shown in Figure 6.
Embodiment 4
With the aperture is that the hydrophobic film of 4.7 μ m places oil loving material to soak into, and makes pore membrane fully moistening to guarantee the complete spread apart of hydrophobic chain on the film.The aqueous acetic acid of preparation 1wt%, add a certain amount of NaCl and under agitation make its dissolving, its concentration is 1wt%, adding certain amount of chitosan then, to make its concentration be 1.5wt%, after treating that it dissolves fully, solution is filtered, add the bovine serum albumin(BSA) (BSA, model drug) of the 20wt% of shitosan dry weight then and fully dissolve standby.Oil soluble emulsifying agent is joined among the mixing oil phase 60ml of atoleine and benzinum, be stirred to fully and dissolve as oil phase.Under certain pressure, the hydrophobic microporous membrane by the aperture homogeneous is pressed in the oil phase, obtains the w/o type emulsion with the water of 6.0g; Slowly drip GST and carry out crosslinked (mol ratio amino and aldehyde radical is 1: 1) in the gained emulsion, crosslinkedly carry out at normal temperatures, the oil phase revolution is 300rpm when crosslinked, and crosslinking time is 2h; Crosslinked end is used benzinum, acetone, ethanol and acetone washing successively with the chitosan microball of gained, and vacuum drying 48h gets the finished product microballoon.The average grain diameter of emulsion adopts the microscope that has scale to measure, surveying 200 averages, average diameter is 11.72 μ m, the CV value is 10.67%, gets dried microballoon 20mg and is scattered in the deionized water continuous stirring 48h, make the complete stripping of bovine serum albumin(BSA) of embedding, the centrifuging and taking supernatant adopts the Bradford method to measure protein content then, and by the embedding rate of calibration curve calculating BSA, the embedding rate of prepared after measured drug bearing microsphere is 90.05%.The optical microscope photograph of drug bearing microsphere as shown in Figure 7.The calibration curve of BSA as shown in Figure 8.
List of references
[1]L.Yang,W.W.Hsiao,P.Chen.,Chitosan-cellulose?composite?membrane?for?affinity?purification?ofbiopolymers?and?immunoadsorption,Journal?of?Membrane?Science,2002,197:185-197.
[2]Xin-Yuan?Shi,Tian-Wei?Tan,Preparation?of?chitosan/ethylcellulose?complex?microcapsule?and?itsapplication?in?controlled?relcase?of?Vitamin?D
2,Biomaterials,2002,23:4469-4473.
[31]
Ruth?Duncan,Evaluation?of?the?biological?properties?of?soluble?chitosan?and?chitosanmicrospheres,International?Journal?of?Pharmaceutics,1997,148:231-240.
[4]T.Hayashi.Y.lkada,Protease?immobilization?onto?porous?chitosan?beads,J.Appl.Polym.Sci.,1991,42:85-97.
[5]Jamees?R.Benson,Highly?Porous?Polymers，American?Laboratory,April?2003.
[6]Gerrit?Borchard,Chitosans?for?gene?delivery,Advanced?Drug?Dclivery?Reviews,2001,52:145-150.
[7]Hai-Quan?Mao,Krishnendu?Roy,Vu?L.Troung-Le,Kevin?A.Janes,Kevin?Y.Lin,Yan?Wang,J.ThomasAugust,Kam?W.Leong,Chitosan-DNA?nanoparticles?as?gene?carriers:synthesis,characterization?andtransfection?efficiency,Journal?of?Controlled?Release,2001,70:399-421.
[8]K.D.Yao,Y.J.Yin,M.X.Xu,F.Wang,Investigation?of?pH?sensitive?drug?delivery?system?of?chitosan/gelatinhybridpolymer?network,Polym.Int.,1995,38:77-89.
[9]Valerie?Dodane,Vinod?D.Vilivalam,Pharmaceutical?applications?of?chitosan,PSTT.Vol.1,No.6,September,1998.
[10]S.T.Lim.G.P.Martin,D.J.Berry,M.B.Brown,Preparation?and?evaluation?of?the?in?vitro?drug?releaseproperties?and?mucoadhesion?of?novel?microspheres?of?hyaluronic?acid?and?chitosan,Journal?of?ControlledRelease,2000.66:281-292.
[11]I.M.Van?der?Lubben,J.C.VerhoeF,G.Borchard,Chitosan?for?mucosal?vaccination,Advanced?Drug?DeliveryReviews,2001.52:139-144.
[12]Futoshi?Shikata,Hiroyuki?Tokumitsu,Hideki?Ichikawa,Yoshinobu?Fukumori,Invitro?cellular?accumulation?ofgadolinium?incorporated?into?chitosan?nanoparticles?designed?for?neutron-capture?therapy?of?cancer,EuropeanJournal?of?Pharmaceutics?and?Biopharmaceutics,2002,53:57-63.
[13]Yong?Yu,Xiqun?Jiang,Yin?Ding,Xaixiong?Ge,Yuyan?Yuan,Changzheng?Yang,Synthesis?andcharacterization?of?chitosan—poly(acrylic?acid)nanoparticles,Biomaterials,2002,23:3193-3201.
Claims (10)
1, the preparation method of a kind of chitosan microball of size homogeneous or micro-capsule is characterized in that (1) water W is the shitosan aqueous acetic acid that has dissolved water soluble drug or disperseed oil-soluble medicine; (2) oil phase O be dissolved oil soluble emulsifying agent and with the immiscible oily matter of water; (3) water is pressed into oil phase with pressure by microporous barrier, obtains the w/o type emulsion droplet of size homogeneous; (4) in the w/o type emulsion of size homogeneous, add crosslinking agent, crosslinked chitosan microball or the micro-capsule of getting.
2, the preparation method of a kind of chitosan microball of size homogeneous or micro-capsule is characterized in that (1) interior oil phase O
1It is the oily matter that has dissolved oil-soluble medicine; (2) interior water W is the aqueous acetic acid that has dissolved water soluble drug and shitosan; (3) outer oil phase O
2Be dissolved oil soluble emulsifying agent, with the immiscible oily matter of water; (4) interior oil phase is mixed with water, be prepared into O with homogeneous phase emulsifier or ultrasonic emulsator
1Behind/W type the colostrum, with this O
1/ W type colostrum is pressed into outer water with pressure by microporous barrier, obtains (the O of size homogeneous
1/ W)/O
2The type emulsion; (5) at (O of size homogeneous
1/ W)/O
2Add crosslinking agent in the type emulsion, crosslinked chitosan microball or the micro-capsule of getting.
3, the preparation method of the chitosan microball of a kind of size homogeneous as claimed in claim 1 or 2 or micro-capsule is characterized in that, the concentration range of chitosan solution is 0.1wt%-10.0wt%.
4, the preparation method of the chitosan microball of a kind of size homogeneous as claimed in claim 3 or micro-capsule is characterized in that, the concentration range of chitosan solution is 0.5-5.0wt%.
5, the preparation method of the chitosan microball of a kind of size homogeneous as claimed in claim 1 or 2 or micro-capsule is characterized in that, water is 1 with the volume ratio of outer oil phase: 1-1: 1000.
6, the preparation method of the chitosan microball of a kind of size homogeneous as claimed in claim 5 or micro-capsule is characterized in that, water is 1 with the volume ratio of outer oil phase: 5-1: 100.
7, the preparation method of the chitosan microball of a kind of size homogeneous as claimed in claim 1 or 2 or micro-capsule is characterized in that, employed microporous barrier surface is a hydrophobicity.
8, the chitosan microball or the micro-capsule of the size homogeneous of method preparation as claimed in claim 1 or 2 is characterized in that, the size homogeneous of microballoon or micro-capsule, and the diameter breadth coefficient is in 20%.
9, the chitosan microball or the micro-capsule of the described a kind of size homogeneous of claim 8 is characterized in that, the embedding rate of hydrophilic medicament or oil-soluble medicine reaches more than 90%.
10, the chitosan microball of a kind of size homogeneous as claimed in claim 8 and micro-capsule is characterized in that, do not have phenomenon, microballoon or the micro-capsule good dispersion of merging between the microballoon.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101002631A CN1319637C (en) | 2003-10-15 | 2003-10-15 | Chitose microsphere and microcapsule with uniform size and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101002631A CN1319637C (en) | 2003-10-15 | 2003-10-15 | Chitose microsphere and microcapsule with uniform size and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1607033A CN1607033A (en) | 2005-04-20 |
| CN1319637C true CN1319637C (en) | 2007-06-06 |
Family
ID=34755895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101002631A Expired - Lifetime CN1319637C (en) | 2003-10-15 | 2003-10-15 | Chitose microsphere and microcapsule with uniform size and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1319637C (en) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100356980C (en) * | 2005-06-02 | 2007-12-26 | 中国科学院过程工程研究所 | Chitosan drug carrying microsphere with uniform size, high embedding rate and high drug activity maintaining rate and its preparation process |
| CN100562322C (en) * | 2005-08-11 | 2009-11-25 | 中国科学院过程工程研究所 | Colon targeting preparation of a kind of 5-aminosalicylic acid and preparation method thereof |
| CN1931370B (en) * | 2006-09-14 | 2010-09-15 | 华东理工大学 | Glycopeptide conjugate microsphere or microcapsule and its preparation process |
| CN101148511B (en) * | 2006-09-18 | 2010-10-20 | 中国科学院过程工程研究所 | Method for preparing fluorescent chitosan micro-sphere and application of the same in tracer field |
| CN101293191B (en) * | 2007-04-25 | 2011-11-09 | 中国科学院过程工程研究所 | Agarose gelatin microsphere preparation method |
| CN101401972B (en) * | 2008-11-07 | 2013-01-02 | 东南大学 | Collagen-chitosan spherical honeycombed grain material, producing method and apparatus thereof |
| CN101401956B (en) * | 2008-11-07 | 2012-11-28 | 东南大学 | Chitosan spherical honeycombed grain material, producing method and apparatus thereof |
| CN101401969B (en) * | 2008-11-07 | 2012-10-24 | 东南大学 | Producing method of collagen-chitosan-hydroxyapatite spherical honeycombed grain material |
| CN101401967B (en) * | 2008-11-07 | 2012-10-24 | 东南大学 | Producing method of collagen-beta-tricalcium phosphate composite spheroidal particle |
| CN101401962B (en) * | 2008-11-07 | 2013-02-27 | 东南大学 | Glutin spherical honeycombed grain material, producing method and apparatus thereof |
| CN101401971B (en) * | 2008-11-07 | 2012-11-28 | 东南大学 | Collagen spherical honeycombed grain material, producing method and apparatus thereof |
| CN101401953B (en) * | 2008-11-07 | 2013-02-27 | 东南大学 | Phosphate biological ceramic microsphere, preparation method and apparatus thereof |
| CN101401957B (en) * | 2008-11-07 | 2013-02-27 | 东南大学 | Chitosan-beta-tricalcium phosphate composite spherical honeycombed grain material, producing method and apparatus thereof |
| CN101401954B (en) * | 2008-11-07 | 2013-01-02 | 东南大学 | Degradable synthetic polymer spherical honeycombed grain material, producing method and apparatus thereof |
| CN101439202B (en) * | 2008-11-07 | 2012-11-28 | 东南大学 | Gelatine-chitosan sphere porous particle material as well as preparation method thereof and device |
| CN101401963B (en) * | 2008-11-07 | 2013-07-03 | 东南大学 | Glutin-beta-tricalcium phosphate composite spheroidal particle, producing method and apparatus thereof |
| CN101401960B (en) * | 2008-11-07 | 2013-04-03 | 东南大学 | Glutin-hydroxyapatite composite spheroidal particle, producing method and apparatus thereof |
| CN101401958B (en) * | 2008-11-07 | 2013-08-07 | 东南大学 | Chitosan-hydroxyapatite composite spheroidal particle, producing method and apparatus thereof |
| CN101401961B (en) * | 2008-11-07 | 2012-10-24 | 东南大学 | Glutin-chitosan-hydroxyapatite spherical honeycombed grain material, producing method and apparatus thereof |
| CN101401970B (en) * | 2008-11-07 | 2013-04-03 | 东南大学 | Collagen-hydroxyapatite composite spheroidal particle, producing method and apparatus thereof |
| CN101401968B (en) * | 2008-11-07 | 2012-10-24 | 东南大学 | Producing method of collagen-chitosan-beta-tricalcium phosphate spherical honeycombed grain material |
| CN101401959B (en) * | 2008-11-07 | 2012-10-24 | 东南大学 | Producing method of glutin-chitosan-beta-tricalcium phosphate spherical honeycombed grain material |
| CN102443088A (en) * | 2011-09-22 | 2012-05-09 | 中国科学院过程工程研究所 | Uniform-size small-particle-size super-macroporous polymer microspheres and preparation method thereof |
| CN102641245B (en) * | 2011-11-02 | 2014-02-26 | 中国科学院过程工程研究所 | Chitosan-chitosan derivative nanosphere for loading indissoluble medicament, preparation method of nanosphere, and application of nanosphere serving as oral prepration |
| CN102658072B (en) * | 2012-05-22 | 2015-12-02 | 江南大学 | The preparation method of single dispersing chitosan hollow microballoon |
| FR2991196B1 (en) * | 2012-05-29 | 2014-06-27 | Capsum | TARGETING NANOPARTICLES FOR BIOLOGICAL APPLICATION |
| KR102203837B1 (en) | 2012-07-05 | 2021-01-15 | 쎈뜨로 나씨오날 데 테끄놀로히아 이 세구리다드 알리멘따리아, 라보라토리오 델 에브로 | Microparticles for the encapsulation of probiotics, preparation and uses thereof |
| CN102921039A (en) * | 2012-10-26 | 2013-02-13 | 浙江大学 | Preparation method of sulfonated chitosan microsphere capable of protecting activity of growth factor |
| CN103834069A (en) * | 2014-02-21 | 2014-06-04 | 武汉大学 | Preparation method of nano-silver-containing magnetic chitin microspheres |
| CN106890159B (en) * | 2015-12-17 | 2020-11-10 | 中国科学院过程工程研究所 | Sodium alginate-agarose microspheres and preparation method and application thereof |
| CN109012615A (en) * | 2018-08-21 | 2018-12-18 | 武汉佰玛生物科技有限公司 | A kind of W/O emulsification prepares chitosan/rectorite composite porous microspheres method |
| CN110694100B (en) * | 2019-10-18 | 2020-10-20 | 清华大学 | Visual drug-loaded embolism microsphere based on liquid metal and preparation method thereof |
| CN113230230A (en) * | 2021-03-29 | 2021-08-10 | 上海工程技术大学 | Oxititinib mesylate microcapsule and mono-coacervation preparation process thereof |
| CN113412870A (en) * | 2021-07-16 | 2021-09-21 | 江门市正平科技创业中心有限公司 | Composition containing dried orange peel extract microcapsule powder and preparation method thereof |
| CN114317513A (en) * | 2021-11-03 | 2022-04-12 | 河北科技师范学院 | Chitosan-carboxymethyl cellulose immobilized enzyme and preparation method thereof |
| CN114471389B (en) * | 2022-01-14 | 2024-08-30 | 厦门大学 | Microfluidic preparation method and application of ocean polymer microspheres |
| CN115501379B (en) * | 2022-08-31 | 2023-05-30 | 中国海洋大学 | Preparation method and application of vascular embolism microsphere with functions of inhibiting tumor angiogenesis and tumor metastasis |
| CN117883405B (en) * | 2023-12-25 | 2024-07-09 | 湖南省博世康中医药有限公司 | Preparation method of rhizoma polygonati instant drink powder based on nano microencapsulation technology |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1373000A (en) * | 2001-02-28 | 2002-10-09 | 中国科学院大连化学物理研究所 | Membrane emulsifying/internal gelatinizing coupled process for preparing gel beads of calcium alginate |
-
2003
- 2003-10-15 CN CNB2003101002631A patent/CN1319637C/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1373000A (en) * | 2001-02-28 | 2002-10-09 | 中国科学院大连化学物理研究所 | Membrane emulsifying/internal gelatinizing coupled process for preparing gel beads of calcium alginate |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1607033A (en) | 2005-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1319637C (en) | Chitose microsphere and microcapsule with uniform size and its preparation method | |
| Mitra et al. | Chitosan microspheres in novel drug delivery systems | |
| CN107855080B (en) | Polymer gel particle, preparation method thereof, composite gel particle containing polymer gel particle and application | |
| Arya et al. | Electrospraying: a facile technique for synthesis of chitosan‐based micro/nanospheres for drug delivery applications | |
| Sahil et al. | Microsphere: A review | |
| Lee et al. | Long acting injectable formulations: the state of the arts and challenges of poly (lactic-co-glycolic acid) microsphere, hydrogel, organogel and liquid crystal | |
| CN100417417C (en) | Surface-modified hydrophobically modified drug-carried chitosan polymer micelle and method for preparing same | |
| Moradi Bidhendi et al. | Design and evaluate alginate nanoparticles as a protein delivery system | |
| CN102138904A (en) | Self-solidified microspheres and preparation method and application thereof | |
| CN109568294B (en) | Controllable preparation method of zwitterionic nano-polymer capsule | |
| CN109464424B (en) | Intestinal administration carrier sulfhydrylation calcium alginate microspheres and preparation method thereof | |
| CN1718616A (en) | Medical intelligent nano-gel material and its preparation method | |
| Guo et al. | Enhanced drug release from a pH-responsive nanocarrier can augment colon cancer treatment by blocking PD-L1 checkpoint and consuming tumor glucose | |
| CN111269443B (en) | Nanogel based on dynamic chemical bond crosslinking and preparation method and application thereof | |
| CN108126211B (en) | Preparation method of nano hybrid particles, nano hybrid particles obtained by preparation method and nano medicine | |
| Sanjanwala et al. | Polysaccharide-based hydrogels for drug delivery and wound management: a review | |
| CN110585136A (en) | Biotin-modified trimethyl chitosan nanoparticles loaded with protein polypeptide and preparation method thereof | |
| AU2003205106A8 (en) | Pace-a microspheres for delivery of antigens | |
| Grabnar et al. | Physicochemical characterization of protein-loaded pectin-chitosan nanoparticles prepared by polyelectrolyte complexation | |
| Priya Dasan et al. | Polymer blend microspheres for controlled drug release: the techniques for preparation and characterization: a review article | |
| CN101836970A (en) | Polyacrylic acid nano-gel microspheres, preparation method and application thereof | |
| Sezer et al. | Comparison on in vitro characterization of fucospheres and chitosan microspheres encapsulated plasmid DNA (pGM-CSF): Formulation design and release characteristics | |
| CN1931129A (en) | Process of preparing biodegradable magnetic medicine carrying polymer microsphere | |
| CN1931370A (en) | Glycopeptide conjugate microsphere or microcapsule and its prepn process | |
| CN110302146B (en) | Preparation and application of injectable attapulgite composite supramolecular hydrogel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20070606 |
|
| CX01 | Expiry of patent term |